Diplomat Pharmacy (DPLO) Misses Q3 EPS by 3c, Offers Guidance

Diplomat Pharmacy (NYSE: DPLO) reported Q3 EPS of $0.21, $0.03 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $1.18 billion versus the consensus estimate of $1.26 billion.

GUIDANCE:

Diplomat Pharmacy sees FY2016 EPS of $0.83-$0.87, versus the consensus of $0.93. Diplomat Pharmacy sees FY2016 revenue of $4.4-4.6 billion, versus the consensus of $4.67 billion.

For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.

You May Also Be Interested In

• Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance
• Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
• UBS Reiterates Neutral Rating on Carter's (CRI)